Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate NDA Resubmission and PDUFA
Unicycive Therapeutics announced the FDA accepted its resubmitted NDA for Oxylanthanum Carbonate (OLC), setting a PDUFA target action date of March 25, 2027. The resubmission addresses manufacturing deficiencies cited in a prior CRL. OLC is an investigational phosphate binder for CKD patients on dialysis, with potential market advantages due to its formulation.
How this was made
The 30-second read
Why it matters
The acceptance resets the timeline for potential approval, giving investors a clearer horizon but also exposing the company to further regulatory scrutiny.
Market read
Regulatory progress for a niche drug candidate; may attract speculative interest in the biotech space.
What to watch
The reliance on a third‑party manufacturer introduces supply‑chain risk that could affect valuation.
Background
Unicycive Therapeutics resubmitted its NDA for Oxylanthanum Carbonate after a Complete Response Letter, receiving FDA acceptance and a Class II review with a six‑month PDUFA clock.
Market effects
Potential boost to the renal‑therapy and phosphate‑binder sector if approval is granted.
Limited to US biotech investors; no broad regional effect.
Minor global impact, confined to specialty pharma niche.
Counterpoint
Approval is not guaranteed; FDA may request additional data, which could delay or derail the product.
Key entities
- companyUnicycive Therapeutics, Inc.
Biopharma developing Oxylanthanum Carbonate for hyperphosphatemia in CKD patients.
- executiveShalabh Gupta, M.D.
CEO of Unicycive Therapeutics, commenting on the FDA acceptance.
